Division of Hematology/Oncology


faculty photo

Peter J. O'Dwyer, M.D.

Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Department: Medicine

Contact information
16 Penn Tower
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-662-7606
Fax: 215-349-8551
University of Dublin, Trinity College Dublin, Ireland, 1975.
Post-Graduate Training
Rotating Internship, Internal Medicine and Surgery , Sir Patrick Dun's Hospital, Dublin, Ireland, 1975-1976.
Senior House Officer, Department of Renal Medicine and Hematology, Hammersmith Hospital, London, England, 1976-1977.
Resident, Pediatrics, Waterbury Hospital, Waterbury, Connecticut, 1977-1979.
Senior House Officer, Department of Rheumatology, Hammersmith Hospital, London, England, 1977-.
Resident, Internal Medicine, Greater Baltimore Medical Center, Baltimore, Maryland, 1979-1981.
Fellow, Oncology, Baltimore Cancer Research Cancer, University of Maryland Hospital, Baltimore, Maryland, 1981-1982.
Fellow, American College of Physicians, .
American Boards of Pediatrics, .
American Boards of Internal Medicine, .
Subspecialty Boards in Medical Oncology, .
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL: Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV. 2003 Notes: Manuscript submitted.

Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ: Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy. Cancer Chemother Pharmacol 2003 Notes: In Press.

Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors. 2003 Notes: In Press.

Yao KS, O’Dwyer PJ: Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. Biochem Pharmacol 2003 Notes: In Press.

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI: Gene expression patterns in epithelial ovarian carcinomas. 2003 Notes: Manuscript submitted.

Flaherty KT, O'Dwyer PJ: Phase II trials in oncology. Anticancer Drug Development Guide. Teicher BA (eds.). 2003 Notes: In Press.

Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy. Drug Resistance Updates 2003 Notes: In Press.

O’Dwyer PJ, Johnson SW: Current status of oxaliplatin in colorectal cancer. Semin Oncol 30(3 Supp 6): 78-87, 2003.

Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ: Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. 2003 Notes: Manuscript submitted.

Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ: Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. 2003 Notes: Manuscript submitted.

back to top
Last updated: 05/20/2014
The Trustees of the University of Pennsylvania

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter